Spread through air spaces (STAS) in stage I lung adenocarcinoma under the new IASLC/WHO pathological grading system: research progress on prognostic value-narrative review.
- 1Department of Thoracic Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China.
- 2Department of Critical Care Medicine IV, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Abstract
Despite complete surgical resection, stage I lung adenocarcinoma exhibits a postoperative recurrence rate of 15-27%, exposing the prognostic limitations of the current Tumor Node Metastasis (TNM) staging system. While the 2020 International Association for the Study of Lung Cancer (IASLC) three-tier grading system significantly improves risk stratification based on high-grade morphological components, it does not incorporate tumor spread through air spaces (STAS), a recognized independent adverse prognostic factor. This review aims to systematically examine the incremental prognostic value of STAS within the framework of the new IASLC grading system and explore its clinical implications. A comprehensive literature search was conducted using the PubMed database to retrieve relevant English-language studies. The review synthesized evidence focusing on the distribution of STAS across histological subtypes, its dose-response relationship with high-grade components, its impact on surgical decision-making, and the critical diagnostic distinction between true STAS and ex vivo artifacts. Current evidence reveals a significant dose-response relationship between STAS and high-grade patterns; notably, the presence of even 5% high-grade components substantially elevates the risk of STAS. Retrospective cohorts consistently demonstrate that STAS strongly predicts disease-free survival and is a critical risk factor for local recurrence following sublobar resection. Crucially, STAS-positive IASLC Grade 2 tumors exhibit recurrence risks overlapping with those of Grade 3, supporting an "upstaging hypothesis" that warrants prospective validation. Furthermore, the clinical translation of STAS remains constrained by the high false-negative rates of intraoperative frozen sections and the ongoing debate regarding artifactual floaters. Integrating STAS status as a collaborative parameter with the IASLC grading system constitutes a conceptual synthesis rather than an established clinical framework for stage I lung adenocarcinoma without necessitating additional molecular testing. Because the current evidence is based predominantly on retrospective data, prospective randomized controlled trial (RCT) validation is required before this approach can be regarded as best clinical practice.
Related
- Cross-Platform External Validation of a Locked 12-Gene Prognostic Panel in Lung Adenocarcinoma Benchmarked Against Pathological Stage.
- Clinical recognition, management, and research progress of infantile perianal protrusion: a narrative review and literature-based case aggregation
- Research progress on developmental characteristics and clinical intervention of restricted and repetitive interests/behaviors in autism spectrum disorder across the lifespan: a narrative review
- Research progress on Bergenia purpurascens: a narrative review
- Progress in pharmacovigilance research based on artificial intelligence and real-world data: a structured narrative review.
BibTeX
@article{pan2026spread,
title = {{Spread through air spaces (STAS) in stage I lung adenocarcinoma under the new IASLC/WHO pathological grading system: research progress on prognostic value-narrative review.}},
author = {Guanghao Pan and Guang Yang and Wenhao Wang and Jianling Su and Huining Liu},
journal = {Journal of thoracic disease},
year = {2026},
month = sep,
doi = {10.21037/jtd-2026-1741},
url = {https://europepmc.org/article/MED/42996658},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Spread through air spaces (STAS) in stage I lung adenocarcinoma under the new IASLC/WHO pathological grading system: research progress on prognostic value-narrative review.
AU - Guanghao Pan
AU - Guang Yang
AU - Wenhao Wang
AU - Jianling Su
AU - Huining Liu
PY - 2026
DA - 2026/09/28
JO - Journal of thoracic disease
DO - 10.21037/jtd-2026-1741
UR - https://europepmc.org/article/MED/42996658
AB - Despite complete surgical resection, stage I lung adenocarcinoma exhibits a postoperative recurrence rate of 15-27%, exposing the prognostic limitations of the current Tumor Node Metastasis (TNM) staging system. While the 2020 International Association for the Study of Lung Cancer (IASLC) three-tier grading system significantly improves risk stratification based on high-grade morphological components, it does not incorporate tumor spread through air spaces (STAS), a recognized independent adverse prognostic factor. This review aims to systematically examine the incremental prognostic value of STAS within the framework of the new IASLC grading system and explore its clinical implications. A comprehensive literature search was conducted using the PubMed database to retrieve relevant English-language studies. The review synthesized evidence focusing on the distribution of STAS across histological subtypes, its dose-response relationship with high-grade components, its impact on surgical decision-making, and the critical diagnostic distinction between true STAS and ex vivo artifacts. Current evidence reveals a significant dose-response relationship between STAS and high-grade patterns; notably, the presence of even 5% high-grade components substantially elevates the risk of STAS. Retrospective cohorts consistently demonstrate that STAS strongly predicts disease-free survival and is a critical risk factor for local recurrence following sublobar resection. Crucially, STAS-positive IASLC Grade 2 tumors exhibit recurrence risks overlapping with those of Grade 3, supporting an "upstaging hypothesis" that warrants prospective validation. Furthermore, the clinical translation of STAS remains constrained by the high false-negative rates of intraoperative frozen sections and the ongoing debate regarding artifactual floaters. Integrating STAS status as a collaborative parameter with the IASLC grading system constitutes a conceptual synthesis rather than an established clinical framework for stage I lung adenocarcinoma without necessitating additional molecular testing. Because the current evidence is based predominantly on retrospective data, prospective randomized controlled trial (RCT) validation is required before this approach can be regarded as best clinical practice.
SN - 2072-1439
SN - 2077-6624
ER -